Artemis Medicare Q1 FY27: consolidated PAT +48% YoY on margin expansion to 19.6% OPM
PAT +48.33% YoY · revenue +12.69% · margins expanding
₹287.32 Cr
+12.69% YoY
₹31.44 Cr
+48.33% YoY
10.74%
+2.7pp YoY
₹1.98
Artemis Medicare's consolidated Q1 FY27 (quarter ended June 30, 2026) print is a clean beat on both lines and on margin trajectory. Consolidated revenue rose 12.7% YoY to ₹287.32 Cr (up 2.9% QoQ from ₹279.23 Cr), while consolidated PAT jumped 48.3% YoY to ₹31.44 Cr (+3.8% QoQ from ₹30.28 Cr) — with no exceptional items in either the current or year-ago quarter, so the reported and adjusted growth numbers are identical. Standalone tells a very similar story: PAT of ₹31.05 Cr, up ~45.0% YoY, a divergence of roughly 3 points from the consolidated pace, explained by the Cardiac Care subsidiary's incremental contribution rather than any accounting distortion.
Q1 FY-2027 vs prior quarters
The entire beat sits on the margin line. Consolidated OPM (EBITDA/revenue, computed as revenue less operative, employee and other expenses) expanded to 19.6% from 16.2% a year ago and 18.5% last quarter; NPM improved to 10.7% from 8.1% YoY. That is notable against management's own May 2026 guidance, which had flagged a temporary 1–1.5% consolidated EBITDA margin drag and an initial ₹18–20 Cr loss from the new Raipur facility ramping up in Q1 FY27 — none of that drag shows up in this quarter's numbers; margins moved the opposite way. One caveat: the Raipur hospital (Artemis Shanti) was formally launched only on July 9, 2026, after this quarter's June 30 close, even though Annexure A already counts ~300 Raipur beds as existing capacity — so the guided margin hit may simply not have hit the P&L yet rather than having been avoided. Management had separately guided the flagship Gurugram hospital to grow revenue 15–17%; the filing gives no city/hospital-level revenue split, so that specific claim can't be directly verified, and total consolidated revenue growth of 12.7% runs below that band regardless.
The stock went into the print at ₹302.2, up 15.8% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Consolidated basic EPS ₹1.98 (not annualised) vs ₹1.35 YoY and ₹1.90 QoQ
Subsidiary Artemis Cardiac Care contributed ₹0.38 Cr PAT on ₹5.32 Cr revenue — non-controlling interest share of consolidated PAT was ₹0.13 Cr
Management is guiding for an aggressive expansion from 800 to over 2,000 beds by 2029, driven by new hospitals in Raipur (Q1 FY27) and South Delhi (FY29). While the new Raipur facility is expected to cause a temporary 1-1.5% drag on consolidated EBITDA margins with an initial INR 18-20 crore loss, this is anticipated t
— This quarter: beat
We found no Q1 FY27-specific street estimates for revenue or PAT in a search of brokerage previews — coverage exists (an Anand Rathi-hosted call is set for August 4, and full-year FY26-27 consensus points to ~30.6% earnings and ~20.3% revenue CAGR per Simply Wall St) but no pre-print quarterly number, so vsStreet is unknown rather than assumed. No separate management press release was available in the context to cross-check framing. The same board meeting also approved a Tower IV expansion at the Gurugram flagship — 200+ beds for quaternary pediatric and advanced gynecology/women's health care, ~₹160–180 Cr over ~2 years funded via internal accruals and debt — consistent with the previously guided 800-to-2,000+ bed roadmap through FY29. Gurugram flagship utilization stood at 65.7% in Q1 FY27, the base management is expanding against.
W1
Whether the guided 1-1.5% consolidated EBITDA margin drag and ₹18-20 Cr initial loss from Raipur shows up in Q2 FY27, given the hospital formally launched July 9, 2026, after this quarter closed
W2
Tower IV execution pace against the ~₹160-180 Cr capex budget and ~2-year timeline, and the accruals-vs-debt funding split
W3
Gurugram flagship capacity utilization trend from the 65.7% Q1 FY27 base as Tower IV's 200+ beds are added
Figures in ₹ Lacs in source, converted to ₹ Cr; no exceptional items in either Q1 FY27 or Q1 FY26 columns so raw=adjusted growth; consolidated PAT ₹31.44 Cr is pre-NCI (matches our DB convention), of which ₹31.31 Cr is attributable to shareholders and ₹0.13 Cr to non-controlling interest (subsidiary Artemis Cardiac Care, which posted ₹0.38 Cr PAT on ₹5.32 Cr revenue).
Strong Core, Expansion Tax Ahead — Why the Overbought Signal Matters More Than the 48% Profit Jump
Artemis delivered textbook guidance (Gurgaom +15.4%, consolidated PAT +48.3%), but the real story begins next quarter: Raipur's ₹20 Cr loss will compress margins, and the stock is already priced for flawless execution on a multi-year capex plan.
Q1 FY-2027 is textbook: revenue ₹287.3 Cr (+12.7% YoY), PAT ₹31.4 Cr (+48.3% YoY), EBITDA margin 21.5% — exactly on the prior guidance trajectory. Gurgaom, the flagship, delivered +15.4% standalone growth with occupancy at 65.7% and ARPOB of ₹85,690 (the highest in the NCR market). The Raipur 300-bed facility went live on schedule (OPD 9 July, full operations 27 July), and within three weeks complex surgeries — commando oncology, advanced cardiology — were already operational. By every metric of execution, management delivered what it promised. But this quarter is not the story going forward. The story is what happens next.
The Margin Peak
The 48.3% PAT growth on just 12.7% revenue growth is the result of operating leverage from Gurgaom's scale and margin expansion. But here's what matters: consolidated EBITDA margin of 21.5% in Q1 is the highest the company will report for the next 12–15 months. Management is guiding for a 1–1.5 percentage-point drag on consolidated margins starting Q2 as Raipur ramps up and begins to bleed ₹20 Cr in operating losses over 15–18 months to breakeven. That loss is real. It's on the books. And it compresses the headline right when the market will be scrutinizing momentum.
Gurgaom +15–17% medium-term revenue growth
Q1 delivered +15.4% standalone; occupancy 65.7%, ARPOB ₹85,690, Q2 target 70%
Supported — on track
Raipur 300-bed live by end-Q1 FY27; complex surgeries within months
Live 9–27 July (within Q1); commando oncology, advanced cath lab, EP, neurosurgery all operational by week 3
Supported — exceeded pace expectation
₹20 Cr operating loss over 15–18 months; break-even Q4 FY28–Q1 FY29
Consistent with prior ₹18–20 Cr guidance; 3 weeks operational, too early to confirm but no contradictions
Supported — but execution risk on occupancy ramp & insurance empanelment
Tower IV 200+ beds, ₹55 lakhs/bed all-in capex, 8–10 months breakeven post-launch
Architectural finalization underway; ₹120 Cr total capex; 50% occupancy by 6 months, full breakeven 8–10 months
Supported — timelines reasonable but subject to regulatory approvals
2,000-bed system, ₹2,000 Cr revenue feasible from Gurgaom alone (900–950 beds) by 2029–30
Analyst model: 70% occupancy, 85% census, 4–5% ARPOB growth over 3–5 years; MD confirmed feasible
Supported — quantified but 3+ years out; dependent on flawless capex execution
International patient mix 27% in Q1; Q2 target 30% despite West Asian war
27% confirmed; no single-region dependency; diversified sourcing (Middle East, Africa, CIS, others)
Supported — resilient but war-dependent
What changed on this call
Raipur traction faster than guided — complex surgeries live at week 3 vs. phased ramp expected
Tower IV now positioning as pediatric + obstetric tertiary/quaternary center ('nodal referral center for NCR') — refined from multi-specialty expansion signal
Daffodils hub-and-spoke model pivoting to consolidation within 3–4 years — smaller centers capacity-constrained, no longer independent growth engines
Insurance empanelment timeline clarity: 8–10 weeks target (faster than 3–4 month industry norm) via CII provider-payer platform co-chaired by MD
Organization structure at succession juncture — MD (20+ years in role) planning to 75; organogram & succession specifics deferred to offline
The bull-bear ledger
Gurgaom core business is fortress-strong: +15.4% YoY, highest ARPOB in NCR (₹85,690), occupancy path to 70% credible
Raipur execution risk lower than expected: complex surgeries live at 3 weeks signals demand and operational maturity
Capex plan is funded and realistic: ₹800 Cr over 3 years; ₹150 Cr annual accrual capacity + debt + ₹700 Cr QIP for brownfield M&A
Consolidated margin will compress 1–1.5pp for 12–15 months while Raipur ramps; that loss is a headwind, not a feature
Insurance empanelment at Raipur is critical path: 8–10 week target is aspirational; any delay extends revenue ramp and loss period
Daffodils, Artemis Lite, Cardiac Care underperforming; strategy to consolidate 3–4 years hence signals current strategy not working, near-term drag real
Organization bandwidth unresolved: multi-city expansion (Raipur, Tower IV, VIMHANS South Delhi) while MD succession plan opaque; organogram details deferred
Stock is overbought (RSI 76, ATH −2.65%, above SMA20/50/200); expansion story is priced in; no institutional fresh buying (FII flat, DII trimming)
Risks, ranked by how much they should concern a holder
Raipur insurance empanelment delayed beyond 8–10 weeks
MediumPatient ramp stalls if direct empanelment misses; TPA intermediary is lower-yield bridge. Break-even extends past 15–18 months; loss period bleeds into FY29. Confidence in 8–10 week timeline depends on CII/IRDA coordination, not guaranteed.
Gurgaom occupancy plateaus at 65–68% (misses 70% Q2 target)
MediumTower IV capex rationale is occupancy ceiling constraint ('inflection point'). If demand is softer, ROI on ₹120 Cr Tower IV capex is questioned. Signals market saturation or pricing pressure; consolidated growth trajectory weakens.
Organization bandwidth at multi-city expansion + MD succession juncture
MediumRaipur, Tower IV, VIMHANS South Delhi execution running in parallel. Dr. Devlina built Artemis for 20+ years; succession plan opaque (organogram deferred). Execution risk real if talent pipeline & controls not bulletproof.
Daffodils/Lite/Cardiac consolidation accelerated or triggered by profitability cliff
LowSmaller centers are ~3–5% of consolidated revenue but underperforming. If consolidation happens sooner than 3–4 years, one-time charges + patient attrition risk. Near-term drag on headline growth.
Competitive pediatric entry (Rainbow Children's in Gurgaom) pressures Tower IV economics
MediumTower IV positions as tertiary/quaternary pediatric + obstetric center, but standalone pediatric hospitals may appeal on specialization. If Tower IV pediatric differentiation weak, capex return eroded.
What to watch next
1 · Q2 occupancy at Gurgaom (70% target confirmation)
This is the linchpin. If occupancy hits 70% as guided, demand narrative holds, Tower IV capex confidence high. If occupancy misses (65–68% range), growth trajectory questions emerge and valuation re-rates. Watch for patient admission data, ARPOB sustainability, and any capacity constraint commentary.
2 · Raipur insurance empanelment timeline + occupancy ramp (September target window)
Insurance is the gate to patient velocity. 8–10 week target from late-July launch = early-September empanelment. If empanelment occurs on schedule, patient ramp & revenue lift visible in Q2–Q3 filings. If delayed, expect extended TPA intermediary dependency (lower yield) and revised break-even guidance to 18–24 months.
3 · Tower IV construction commencement + regulatory approvals (H2 FY27 milestone)
18–22 month operationalization timeline depends on immediate construction start and regulatory closure (FAR increase, architectural approvals, fire/safety). Any slip in H2 pushes operationalization into FY29; delays cascade into margin accretion thesis. Watch for permit updates, capital deployment pace, and revised timelines on Q2+ earnings calls.
4 · QIP asset finalization + fundraising launch (6–8 month timeline expected)
₹700 Cr QIP is flagged as 'enabling resolution' for brownfield M&A, not announced projects (Raipur, Tower IV, VIMHANS self-funded). Asset quality & timing fluid. Watch for: ICICI asset appraisal completion, shareholder dilution estimates, and any new acquisition announcements.
The street's verdict
The result announcement on 3 August triggered a day-1 dip of −0.23%, followed by a day-3 recovery of +3.14%. That pattern — brief skepticism, then recovery — tells you the street's own read: solid delivery, but not a surprise. The stock is now at ₹316.3 (as of 7 August), up 55.54% from its 52-week low of ₹203.35, but only −2.65% from its all-time high of ₹324.9. RSI is 76.2, deep into overbought territory. Moving averages are all bullish (price above SMA20, SMA50, SMA200), but valuation is fully loaded for the expansion story.
Institutional flows tell the real story. FII ownership is 12.29% (up a modest 0.1 percentage point QoQ), and DII ownership is 2.40% (down 0.49 percentage points). Domestic institutions are trimming, not adding. That's a red flag when the stock is at ATH and momentum is high. It suggests sophisticated money sees limited upside from here — the expansion story is priced in, and the near-term margin compression from Raipur ramp is a headwind that hasn't yet shown up in the tape.
Earnings quality & key takeaways
Q1 earnings are clean — no one-time items, no MTM gains, no tax surprises distorting the PAT print. The 48.3% PAT growth is organic, driven by Gurgaom's scale and margin expansion. But that expansion will be muted starting Q2 as Raipur bleeds. Here's what you need to track from here:
21.5% (Q1 peak)
Watch for 20–20.5% range starting Q2 as Raipur loss kicks in
Early-stage (3 weeks)
Critical: insurance empanelment by Sep 2026. If delayed, revenue ramp pushes right.
65.7% in Q1, 70% targeted
Linchpin for tower IV ROI case. Miss signals growth plateau.
18–22 mo timeline
Regulatory closures & capex pace critical. Any H2 slip cascades to FY29 ops start.
Artemis is a steady franchise, not a step-change. Q1 delivers exactly what management promised: Gurgaom +15.4%, consolidated PAT +48.3%, Raipur on time. But the stock is overbought (RSI 76, ATH −2.65%), the expansion story is priced in, and the near-term (next 12–15 months) is margin compression, not growth. Institutions are trimming. The honest read is a 70/30 bet: 70% confidence the long-term plan (₹2,000 Cr revenue, 2,000 beds by 2029–30) is executable; 30% risk that near-term hiccups (insurance delays, occupancy miss, organization bandwidth) cost you 15–20% upside while you wait. At ATH, that's a HOLD. The number to track is consolidated EBITDA margin starting Q2; anything below 20% signals Raipur ramp-up is heavier than guided.
Strong Q1 profit growth; expansion on track despite Raipur drag
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B+
Met prior Raipur launch guidance; on track for 15–17% Gurgaom growth; 2,000-bed timeline confirmed. Raipur only 3 weeks old (too early to confirm execution); Daffodils/Lite underperformance unexplained.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q1 delivery (12.7% revenue, 48.3% PAT growth) with clear expansion roadmap (2,000 beds by 2029–30, ₹800 Cr capex plan). Gurgaom core business healthy (15.4% standalone growth, margin expansion to 20–21%). Key risk: Raipur ramp-up uncertainty—₹20 Cr loss headwind, insurance empanelment dependency (8–10 weeks), and organization bandwidth at MD succession juncture temper enthusiasm.
₹287.32 Cr
Revenue · +12.7% YoY₹31.44 Cr
Reported PAT · +48.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Consolidated revenue ₹287.32 Cr with 12.7% YoY growth
METDelivered ₹287.3 Cr, +12.7% YoY. Gurgaom standalone +15.4%.
EBITDA ₹61.82 Cr at 21.5% margin, PAT ₹31.44 Cr, +48.3% YoY
MET21.5% of ₹287.3 = ₹61.8 Cr ✓; PAT ₹31.4 Cr confirmed; growth rate matches.
Gurgaom occupancy 65.7%, ARPOB ₹85,690; targeting 70% by Q2
METOccupancy improving; occupancy constraint cited as rationale for Tower IV expansion. Q2 reaffirmation of prior 70% target.
Raipur 300-bed hospital commenced operations; break-even 15–18 months, loss ~₹20 Cr
METSoft launch 9 July (OPD), full ops 27 July (theaters/cath labs). Complex surgeries (commando) happening. ₹20 Cr loss estimate aligns with prior ₹18–20 Cr guidance.
International patient mix 27% despite West Asian war; Q2 outlook 30%
MET27% reported; no single regional dependency; Q2 guidance realistic given diversification strategy.
Gurgaom margins to reach 23–24% within 2–3 years; ₹2,000 Cr top line by 900–950 beds feasible
METQuantified margin target new; revenue model (70% occupancy, 85% census, 4–5% ARPOB growth) provided by analyst, confirmed by MD.
Tower IV 200+ beds, ₹55 lakhs/bed, operational 18–22 months, 8–10 mo breakeven
METCapex ₹120 Cr total; 50% occupancy by 6 mo, full breakeven 8–10 mo post-launch. Timelines consistent.
Earnings quality
What changed since the last call
Raipur traction better than guided
UpgradeComplex surgeries (commando oncology) already live at 3 weeks vs. expected phased ramp. OPD, cath labs, neurosurgery operational together. Suggests faster patient acquisition feasible.
Tower IV now pediatric + women-focused
NeutralOriginally implied multi-specialty expansion; now positioned as dedicated pediatric tertiary/quaternary + obstetrics/gynecology tower to become 'nodal referral center for NCR.' Marketing/positioning shift, not economics.
Daffodils consolidation accelerated
DowngradePrior calls implied sustained hub-and-spoke model. Now: 'consolidate within 3–4 years'; smaller centers have capacity constraints limiting growth. Strategic pivot away from saturation via independent satellite centers.
Insurance empanelment timeline clarity
NeutralRaipur insurance 8–10 weeks expected vs. prior 3–4 months industry norm. Benefit of provider-payer CII platform mediation (MD co-chairing working group). Supports faster ramp but execution risk remains.
The Q&A
Analysts pressed hard on capex ratios (₹55 lakhs/bed vs. ₹120 lakhs greenfield), organization bandwidth (Dr. Devlina succession, organogram deferred), and Daffodils underperformance. Management held firm on expansion thesis but deflected center-wise splits & succession specifics. Tone: confident but cautious on brownfield timing & QIP dilution.
International mix resilience — Aditya Chheda, InCred Asset
Answered27% in Q1 despite war; no single regional dependency; multi-country sourcing; Q2 target 30%. Overall volume not compromised vs. peers.
Tower IV capacity math — Aditya Chheda, InCred Asset
AnsweredCombined: 130–150 beds from platinum rating free + 70 beds FAR purchased = 200+ total. Timeline 18–22 months.
Gurgaom margin trajectory — Sumit Gupta, Antique Stock
AnsweredYes, absolutely. Economies of scale, case mix improvement, manpower efficiency drive expansion.
Raipur traction — Sumit Gupta, Antique Stock
PartialEncouraging: OPD 9 July, theaters 27 July, complex surgeries live. 15–18 mo to break-even, ₹20 Cr loss. Occupancy early; detailed Q2 update promised.
Margin drivers consolidated — Aadesh Gosalia, Spark PWM
AnsweredEconomies of scale (fixed costs spread), case mix improvement (ARPOB highest in NCR), smaller centers + cardiac improving. Adding 200 beds will expand margins further.
Raipur specialties & capex — Abin Benny, JM Financial
AnsweredAll major specialties live simultaneously: advanced cath lab, EP, neurosurgery, onco, trauma. Total capex ₹120 Cr (80% done). PET-CT & radiotherapy finishing by end-Aug.
Tower IV cross-integration — Abin Benny, JM Financial
AnsweredNo separate team; already doing tertiary/quaternary pediatric care in-house. Tower IV consolidates under one roof for brand positioning, not new capability.
Tower IV occupancy impact — Abin Benny, JM Financial
AnsweredNo; Gurgaom will reach 70–72% occupancy by end-FY27, so Tower IV beds will absorb demand without patient denial. No net occupancy loss.
QIP timeline — Nandkumar, shareholder
Partial6–8 months for asset finalization before launch. Enabling resolution; quantum & timing fluid based on asset quality & shareholder dilution.
Capex per bed & 3-year plan — Anubhav, Anand Rathi
AnsweredTower IV ₹55 lakhs/bed (all-in). Total ₹800 Cr capex over 3 years (Raipur ₹120 Cr, VIMHANS ₹350–360 Cr, Tower IV ₹120 Cr, parking ₹70–80 Cr, replacement ₹100–120 Cr).
Center-wise revenue/EBITDA split — Vedant, ICICI Securities
DodgedDeferred to offline email for detailed segment data.
Raipur insurance empanelment — Vedant, ICICI Securities
Answered8–10 weeks expected (faster than 3–4 mo norm) via CII provider-payer platform. TPA intermediary bridging cashless experience until direct empanelment.
Competitive intensity pediatric focus — Vedant, ICICI Securities
AnsweredGurgaom has most intense bed competition; we've grown 90→600+ beds via outcomes & ethics. Tower IV showcases tertiary/quaternary services beyond standalone pediatric hospitals' capacity.
Bed capacity ambiguity — Sanidhya, Unicorn Asset
Partial900 minimum (700+200), 980 maximum post-detailed architectural drawings. Raipur traction growing; insurance 8–10 weeks; occupancy targets deferred to Q2 call.
QIP usage & capital allocation — Sreedhar, Blue Hill Capital
AnsweredEnabling resolution; new brownfield acquisitions only (not Raipur/Tower IV/VIMHANS, which are self-funded via accruals & debt). Focus on EBITDA break-even or positive brownfields.
Daffodils strategy — Sreedhar, Blue Hill Capital
PartialHub-and-spoke model initially working; now consolidating centers after maturity (3–4 years) to improve bed economics. No breakup details given.
Organization structure & MD succession — Sreedhar, Blue Hill Capital
PartialPlanning 75 years; full organogram details deferred to offline with Rudra (central teams, regional teams, zonal areas, controls defined).
Tower IV brownfield breakeven — Kumar Saurabh, Scientific Investing
AnsweredBreak-even 8–10 months post-launch (likely H2 FY28 if 18–22 mo operationalization). 50% occupancy by 6 months expected.
Capital structure & dilution minimization — Kumar Saurabh, Scientific Investing
Answered₹450 Cr from accruals over 3 years covers announced projects + debt leverage. QIP for brownfield M&A only to minimize shareholder dilution; thought-through process.
Occupancy & long-term revenue modeling — Neelam Punjabi, Perpetuity Ventures
AnsweredYes, on track for 70% Q2. At 85% census, 70% occupancy, 4–5% ARPOB growth over 3–5 years, ₹2,000 Cr from Gurgaom alone possible with 23%+ margins.
Daffodils muted performance — Neelam Punjabi, Perpetuity Ventures
PartialCapacity constraints in smaller units; hub-and-spoke model served purpose but will consolidate. Rents & manpower outpace topline in limited-bed settings; 3–4 year maturation before consolidation.
Capex breakup clarity — Aditya Chheda, InCred Asset
AnsweredDeposit (₹250 Cr, ₹130 Cr paid) separate from ₹800 Cr capex. Raipur ₹120 Cr, VIMHANS ₹350–360 Cr pure capex, Tower IV ₹120 Cr, parking ₹70–80 Cr, replacement ₹100–120 Cr. Totals ₹600 Cr.
Guidance
Gurgaom +15–17% over medium-term
HighQ1 delivered +15.4% standalone; occupancy 65.7%→70% Q2 on track; Tower IV break-even 8–10 mo supports growth ladder.
Consolidated ₹2,000 Cr revenue from Gurgaom alone
MediumFY29–30 target; assumes 900–950 beds, 70% occupancy, 85% census, 4–5% ARPOB growth. Analyst-driven model, MD confirmed feasible. Execution risk: multi-year horizon.
Raipur break-even 15–18 months post-launch
MediumExpected ₹20 Cr loss; complex surgeries early suggests faster ramp possible. Insurance empanelment (8–10 weeks) critical to revenue trajectory. Timeline: likely Q4 FY28–Q1 FY29.
Gurgaom FY27: 20–21% margins
HighQ1 delivered 21.5% consolidated (Gurgaom higher). Confirmed achievable by MD; economies of scale + case mix.
Gurgaom 2–3 years: 23–24% margins
MediumTower IV + 200-bed expansion, higher-margin pediatric/obstetric focus, manpower efficiency drive upside. Conservative: assumes modest incremental margin expansion from 21.5% current.
Consolidated impact: 1–1.5% drag from Raipur ramp
MediumRaipur loss will compress consolidated margins near-term. Offset by Gurgaom expansion & Tower IV. Net margin trajectory: neutral-to-positive by FY29.
FY27–29 total capex ₹800 Cr
HighRaipur ₹120 Cr, VIMHANS ₹350–360 Cr, Tower IV ₹120 Cr, parking ₹70–80 Cr, replacement ₹100–120 Cr. Deposits (VIMHANS) ₹250 Cr separate.
Tower IV ₹55 lakhs/bed (₹120 Cr for 200+ beds + 450 parking)
HighBrownfield expansion significantly cheaper than greenfield (₹120 lakhs/bed). Parking inclusion inflates per-bed but reflects infrastructure priorities.
VIMHANS 650-bed facility: ₹350–360 Cr + ₹250 Cr deposit (ICICI financed)
MediumAcquisition-in-progress; deposit ₹130 Cr paid. Capital-intensive; integration timeline multi-year. South Delhi presence unlocks hub-and-spoke model.
Risks the call surfaced
Raipur execution
MediumRaipur just 3 weeks old; occupancy trajectory unproven. Management cautious ('very early days'). Break-even 15–18 months assumes steady state; any slip extends loss period.
Insurance empanelment
MediumRaipur insurance critical to patient ramp. Management targeting 8–10 weeks but relies on CII provider-payer platform & IRDA coordination. TPA intermediary is lower-yield bridge.
Occupancy constraints
MediumQ1 occupancy 65.7%; management cites 'inflection point' requiring Tower IV to prevent patient denial. If demand slower than assumed, capex return questioned. If faster, Q2 target 70% delays full ramp.
Daffodils underperformance
LowDaffodils, Artemis Lite, Cardiac Care muted in Q1 (analyst back-calc). Strategy to consolidate after maturity (3–4 years) signals current units unprofitable or low-margin. Q1 drag material if larger than expected.
Competitive intensity
MediumRainbow Children's entering Gurgaom with dedicated pediatric focus. Tower IV positions Artemis as tertiary/quaternary pediatric center, but standalone competitors may appeal on specialization.
Organization bandwidth
MediumDr. Devlina MD for 20+ years; planning to 75. Multi-city model (Raipur, South Delhi, Tower IV) requires distributed management & central controls. Organogram details deferred; succession plan unclear.
Management
Score 8/10. Clear, confident, specific on numbers. Detailed capex breakups, timelines (18–22 months Tower IV, 15–18 months Raipur), occupancy targets. Hedging on Raipur occupancy trajectory & smaller-center performance signals realism. Raipur launch on-time (July vs. end-Q1 guidance), complex surgeries live within 3 weeks. Gurgaom +15.4% delivered vs. 15–17% guidance on track. EBITDA margin 21.5% strong. Prior guidance (2,000-bed plan, ₹18–20 Cr Raipur loss) confirmed. Track record: B+.
1 · Sep 2026
Raipur insurance empanelment (8–10 weeks target); patient ramp traction
2 · Q2 FY27
Occupancy 70% at Gurgaom; detailed Raipur & Tower IV progress update
3 · Dec 2026
QIP asset finalization; expected ₹700 Cr fundraising launch (6–8 mo timeline)
Key risk: Raipur ramp-up uncertainty—₹20 Cr loss headwind, insurance empanelment dependency (8–10 weeks), and organization bandwidth at MD succession juncture temper enthusiasm.